The approval of dabrafenib plus trametinib (D + T) in 2017 marked the first targeted therapy for NSCLC with BRAF V600E mutations, achieving an ORR of 64% and median DOR of 10.6 months [110,111]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.